A comparison of the genetic alterations in recurrent IDH-mutant gliomas with those in the matched newly diagnosed tumors demonstrated a significant number of acquired mutations that are specific to the recurrent tumors [13]. This evidence concerns the gene IDH2 and central nervous system cancer.